<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345056</url>
  </required_header>
  <id_info>
    <org_study_id>MOHEgypt</org_study_id>
    <nct_id>NCT03345056</nct_id>
  </id_info>
  <brief_title>Vitrectomy With Planned Foveal Detachment for Refractory DME With or Without Vitreo-macular Interface Abnormality</brief_title>
  <official_title>Evaluation of Vitrectomy With Planned Foveal Detachment as Surgical Treatment for Refractory Diabetic Macular Edema With or Without Vitreo-macular Interface Abnormality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health and Population, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health and Population, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the therapeutic efficacy of sub retinal BSS injections in conjunction with
      conventional vitrectomy for refractory Diabetic macular edema (DME)- resistant to more than
      one anti-VEGF agent, intravitreal corticosteroids and to previous vitrectomy. Some of
      enrolled cases had normal vitreo-macular interface (VMI) relationship, while other cases had
      incomplete vitreoretinal separation with vitreomacular attachment (VMA).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>central macular thickness decrease</measure>
    <time_frame>10 months postperative</time_frame>
    <description>decrease in central macular thickness by OCT</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Chronic Edema of the Macula</condition>
  <arm_group>
    <arm_group_label>included cases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>vitrectomy done with planned foveal separation and followed for the result</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>vitrectomy with planned foveal detachment</intervention_name>
    <description>23 gauge vitrectomy, posterior hyaloid detachment, internal limiting membrane peeling , sub-macular BSS injection using 38 gauge canula</description>
    <arm_group_label>included cases</arm_group_label>
    <other_name>vitrectomy with submacular BSS injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cases with refractory DME with a central macular thickness (CMT) of more than 300 Âµm
             despite undergoing anti-VEGF therapy (5-6 monthly injections of ranibizumab (IVR) or
             bevacizumab (IVB) with shifting to aflibercept (IVA) for additional 3 injections).

        Exclusion Criteria:

          -  The major exclusion criteria were: (1) presence of apparent retinal pigment epithelium
             (RPE) atrophy at or near the macula; (2) presence of proliferative diabetic
             fibrovascular membranes threating or at the macula; (3) presence of diabetic optic
             atrophy; and (4) presence of neovascular glaucoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Health and Population, Egypt</investigator_affiliation>
    <investigator_full_name>ahmed M. Abdel hadi</investigator_full_name>
    <investigator_title>Assistant professor of ophthalmology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

